PMC:7558914 / 28282-29138
Annnotations
LitCovid_Glycan-Motif-Structure
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T43 | 227-234 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
| T44 | 227-234 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
| T45 | 297-304 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
| T46 | 297-304 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
| T47 | 556-563 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
| T48 | 556-563 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
| T49 | 594-601 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
| T50 | 594-601 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 678 | 239-247 | Species | denotes | patients | Tax:9606 |
| 679 | 309-317 | Species | denotes | patients | Tax:9606 |
| 680 | 456-464 | Species | denotes | patients | Tax:9606 |
| 681 | 533-541 | Species | denotes | patients | Tax:9606 |
| 682 | 572-580 | Species | denotes | patients | Tax:9606 |
| 683 | 227-234 | Chemical | denotes | heparin | MESH:D006493 |
| 684 | 297-304 | Chemical | denotes | heparin | MESH:D006493 |
| 685 | 508-519 | Chemical | denotes | tocilizumab | MESH:C502936 |
| 686 | 556-563 | Chemical | denotes | heparin | MESH:D006493 |
| 687 | 594-601 | Chemical | denotes | heparin | MESH:D006493 |
| 688 | 57-65 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 689 | 104-113 | Disease | denotes | Andalusia | |
| 690 | 264-274 | Disease | denotes | thrombosis | MESH:D013927 |
| 691 | 618-640 | Disease | denotes | venous thromboembolism | MESH:D054556 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T54 | 625-640 | Phenotype | denotes | thromboembolism | http://purl.obolibrary.org/obo/HP_0001907 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T180 | 0-2 | Sentence | denotes | 5. |
| T181 | 3-14 | Sentence | denotes | Conclusions |
| T182 | 15-496 | Sentence | denotes | In conclusion, this study showed that the COVID-19 protocols of the largest hospitals in Andalusia, Spain, varied widely in several aspects, including antiviral treatment; corticosteroids; anakinra; prophylactic heparin for patients at high risk of thrombosis; therapeutic doses of heparin for patients in critical condition or with a progressive increase in D-dimer levels; and different dosage, duration, and combinations of treatment for patients in the same clinical condition. |
| T183 | 497-743 | Sentence | denotes | The use of tocilizumab for selected patients, prophylactic heparin for all patients, therapeutic heparin for evidence of venous thromboembolism, general symptomatic and supportive care, and hospital organization were recommended in all protocols. |
| T184 | 744-856 | Sentence | denotes | Rigorous randomized clinical trials on the proposed interventions are needed in order to provide solid evidence. |